879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab

• Massimo Fantini,
• Kwong Y Tsang,
• Christina Annunziata,
• Philip Arlen,
• Anjum Zaki,
• Sharon Mavroukakis,
• Charalampos S Floudas,
• Jamie Hur,
• Azam Ghafoor,
• Ann McCoy,
• Erica Redmond,
• Christine Feierabend

Affiliations

Massimo Fantini

2Precision Biologics, Inc., Bethesda, MD, USA

Kwong Y Tsang

2Precision Biologics, Inc., Bethesda, MD, USA

Christina Annunziata

1National Institutes of Health (NIH), Bethesda, MD, USA

Philip Arlen

2Precision Biologics, Inc., Bethesda, MD, USA

Anjum Zaki

2Precision Biologics, Inc., Bethesda, MD, USA

Sharon Mavroukakis

2Precision Biologics, Inc., Bethesda, MD, USA

Charalampos S Floudas

3National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA

Jamie Hur

1National Institutes of Health (NIH), Bethesda, MD, USA

Azam Ghafoor

1National Institutes of Health (NIH), Bethesda, MD, USA

Ann McCoy

1National Institutes of Health (NIH), Bethesda, MD, USA

Erica Redmond

1National Institutes of Health (NIH), Bethesda, MD, USA

Christine Feierabend

1National Institutes of Health (NIH), Bethesda, MD, USA